MX345019B - Nuevo anticuerpo ctgf antihumano. - Google Patents

Nuevo anticuerpo ctgf antihumano.

Info

Publication number
MX345019B
MX345019B MX2014007681A MX2014007681A MX345019B MX 345019 B MX345019 B MX 345019B MX 2014007681 A MX2014007681 A MX 2014007681A MX 2014007681 A MX2014007681 A MX 2014007681A MX 345019 B MX345019 B MX 345019B
Authority
MX
Mexico
Prior art keywords
human ctgf
ctgf antibody
seq
amino acid
acid sequence
Prior art date
Application number
MX2014007681A
Other languages
English (en)
Other versions
MX2014007681A (es
Inventor
Iwasaki Shoji
Moriya Ryuichi
Yoshino Masayasu
Takakura Koji
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2014007681A publication Critical patent/MX2014007681A/es
Publication of MX345019B publication Critical patent/MX345019B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un anticuerpo CTGF antihumano que tiene una actividad de unión superior y/o una actividad neutralizante superior en comparación con aquella de los anticuerpos CTGF antihumanos convencionales; y un medio para prevenir o tratar varias enfermedades en las que el CTGF humano está implicado en la formación de condiciones clínicas de los mismos, que incluye las enfermedades renales como la enfermedad renal crónica y la nefropatía diabética, al usar el anticuerpo CTGF antihumano mencionado. Un anticuerpo CTGF antihumano que contiene una región variable de cadena pesada que comprende la secuencia de aminoácidos representada por la SEC ID NO: 10 y una región variable de cadena ligera que comprende la secuencia de aminoácidos representada por SEC ID NO: 4.
MX2014007681A 2011-12-22 2012-12-21 Nuevo anticuerpo ctgf antihumano. MX345019B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011281811 2011-12-22
PCT/JP2012/083206 WO2013094723A1 (ja) 2011-12-22 2012-12-21 新規抗ヒトｃｔｇｆ抗体

Publications (2)

Publication Number Publication Date
MX2014007681A MX2014007681A (es) 2014-11-25
MX345019B true MX345019B (es) 2017-01-11

Family

ID=48668601

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014007681A MX345019B (es) 2011-12-22 2012-12-21 Nuevo anticuerpo ctgf antihumano.

Country Status (16)

Country Link
US (1) US9587015B2 (es)
EP (1) EP2796550B1 (es)
JP (1) JP6040943B2 (es)
KR (1) KR20140107507A (es)
CN (1) CN104011206B (es)
AR (1) AR089425A1 (es)
BR (1) BR112014015405A2 (es)
CA (1) CA2859627A1 (es)
EA (1) EA029290B1 (es)
ES (1) ES2665851T3 (es)
IN (1) IN2014CN04615A (es)
MX (1) MX345019B (es)
PL (1) PL2796550T3 (es)
PT (1) PT2796550T (es)
TW (1) TW201333034A (es)
WO (1) WO2013094723A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109824777A (zh) * 2019-03-15 2019-05-31 辽宁何氏医学院 一种具有抑制玻璃体视网膜纤维化病变作用的单克隆抗体及其制备方法和应用
US20200369759A1 (en) 2019-05-23 2020-11-26 Fibrogen, Inc. Methods of treatment of muscular dystrophies
BR112021023669A2 (pt) * 2019-06-04 2022-03-29 Jiangsu Hengrui Medicine Co Anticorpo do fator de crescimento de tecido anti-conjuntivo e aplicação do mesmo
AU2021390125A1 (en) * 2020-12-03 2023-06-22 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising anti-connective tissue growth factor antibody
JPWO2023238845A1 (es) 2022-06-07 2023-12-14
AR130904A1 (es) 2022-10-31 2025-01-29 Astellas Pharma Inc Conjugado de anticuerpo-fármaco que contiene un compuesto agonista dual del receptor tipo toll 7/8
CN120858112A (zh) * 2023-03-10 2025-10-28 江西康莱特新森医药原料有限公司 一种靶向ctgf的抗体或其抗原结合片段及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE8808645U1 (de) 1988-07-06 1988-08-25 Hofer, Daniel, 7730 Villingen-Schwenningen Anzeigeeinrichtung für Feuerlöscher
ES2213148T3 (es) 1993-03-11 2004-08-16 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Anticuerpo monoclonal dirigido contra el vih.
EP1043335A4 (en) * 1997-12-25 2005-08-31 Japan Tobacco Inc MONOCLONAL ANTIBODY AGAINST THE BIND WEIGHT GROWTH FACTOR AND ITS MEDICAL USES
JP4537507B2 (ja) * 1997-12-25 2010-09-01 アムジェン インコーポレイテッド 結合組織増殖因子に対するモノクローナル抗体及びその医薬用途
EP1140964B1 (en) 1998-12-14 2008-04-09 University Of Miami Connective tissue growth factor (ctgf) fragment
US7115390B1 (en) 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7405274B2 (en) * 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
JP2009067678A (ja) * 2005-12-07 2009-04-02 Nihon Nosan Kogyo Kk 結合組織増殖因子に対する抗体又はそれを含む組成物
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor

Also Published As

Publication number Publication date
PL2796550T3 (pl) 2018-08-31
TW201333034A (zh) 2013-08-16
EA029290B1 (ru) 2018-03-30
PT2796550T (pt) 2018-04-18
MX2014007681A (es) 2014-11-25
WO2013094723A1 (ja) 2013-06-27
AR089425A1 (es) 2014-08-20
BR112014015405A2 (pt) 2017-06-13
JPWO2013094723A1 (ja) 2015-04-27
IN2014CN04615A (es) 2015-09-18
EP2796550A1 (en) 2014-10-29
CA2859627A1 (en) 2013-06-27
CN104011206B (zh) 2017-03-08
EP2796550B1 (en) 2018-02-28
US9587015B2 (en) 2017-03-07
EP2796550A4 (en) 2015-08-19
KR20140107507A (ko) 2014-09-04
US20140343258A1 (en) 2014-11-20
JP6040943B2 (ja) 2016-12-07
CN104011206A (zh) 2014-08-27
EA201491240A1 (ru) 2014-11-28
ES2665851T3 (es) 2018-04-27

Similar Documents

Publication Publication Date Title
MX345019B (es) Nuevo anticuerpo ctgf antihumano.
MX2014001370A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
MX2014001371A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
RU2013140625A (ru) Антитела против ангиопоэтина-2 человека
RU2012137498A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
WO2013011076A3 (en) Tnf -alpha antigen- binding proteins with increased fcrn binding
NZ714516A (en) Human antibodies to clostridium difficile toxins
NZ705848A (en) Anti-cd38 antibodies
WO2009048537A3 (en) Humanized antibody
HRP20170254T1 (hr) Humanizirana i kimerna monoklonska protutijela usmjerena na cd47
EA201201227A1 (ru) Бипаратопные а-бета-связывающие полипептиды
MX351273B (es) Nuevo anticuerpo anti-ngf humano.
WO2013120012A3 (en) Cdim binding proteins and uses thereof
MX2010009190A (es) Anticuerpos anti-c5ar humanizados.
EA201301107A1 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
EA201892184A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
JP2014530215A5 (es)
WO2009048538A3 (en) Use of anti-amyloid beta antibody in ocular diseases
WO2014012007A3 (en) Rspo3 binding agents and uses thereof
WO2013013025A3 (en) Anti-cxcr4 antibodies and methods of use
EA201491235A1 (ru) Варианты полипептидов fc-pol с улучшенным связыванием неонатального рецептора fc
EP2548574A4 (en) NEW HUMANIZED MONOCLONAL ANTIBODY AGAINST CD20
CN104245736A (zh) 抗人死亡受体5胞外区的人源化单克隆抗体
BR112013021860A2 (pt) anticorpo anti-tnfalpha humanizado
BR112014008331A2 (pt) anticorpos sema4a anti-humanos úteis para tratar doença

Legal Events

Date Code Title Description
FG Grant or registration